First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Update

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the recipient of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 19,031 shares, a decline of 85.8% from the August 31st total of 134,463 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 35,950 shares, the days-to-cover ratio is currently 0.5 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Up 0.2%

Shares of First Trust Nasdaq Pharmaceuticals ETF stock traded up $0.10 during trading on Friday, reaching $41.67. The company’s stock had a trading volume of 4,555,603 shares, compared to its average volume of 239,008. First Trust Nasdaq Pharmaceuticals ETF has a 52-week low of $27.40 and a 52-week high of $42.87. The firm’s 50-day moving average is $40.57 and its two-hundred day moving average is $37.06. The company has a market cap of $1.07 billion, a price-to-earnings ratio of 14.51 and a beta of 0.46.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Thursday, September 24th will be paid a $0.0113 dividend. This is a drop from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. This represents a $0.05 annualized dividend and a yield of 0.1%. The ex-dividend date of this dividend is Thursday, September 24th.

Institutional Trading of First Trust Nasdaq Pharmaceuticals ETF

Several institutional investors have recently added to or reduced their stakes in FTXH. Flputnam Investment Management Co. purchased a new position in shares of First Trust Nasdaq Pharmaceuticals ETF in the fourth quarter worth about $230,000. Vivaldi Capital Management LP boosted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 16.0% during the 1st quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock valued at $433,000 after acquiring an additional 1,741 shares during the period. Nilsine Partners LLC grew its position in First Trust Nasdaq Pharmaceuticals ETF by 3.5% during the 2nd quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock worth $1,071,000 after acquiring an additional 937 shares during the last quarter. Finally, Compass Financial Management LLC bought a new position in First Trust Nasdaq Pharmaceuticals ETF during the 2nd quarter worth approximately $29,000.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.